| Name | cytochrome P450 (protein family or complex) |
|---|---|
| Synonyms | cytochrome P450; cytochrome P 450; CYP450; CYP 450 |
| Name | piperazine |
|---|---|
| CAS | piperazine |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 14698036 | Staack RF, Paul LD, Springer D, Kraemer T, Maurer HH: Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP). Biochem Pharmacol. 2004 Jan 15;67(2):235-44. |
81(1,1,1,1) | Details |
| 15056479 | Wojcikowski J, Pichard-Garcia L, Maurel P, Daniel WA: The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208. |
32(0,1,1,2) | Details |
| 14985146 | Staack RF, Theobald DS, Paul LD, Springer D, Kraemer T, Maurer HH: In vivo metabolism of the new designer drug 1-(4-methoxyphenyl) piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step. Xenobiotica. 2004 Feb;34(2):179-92. |
32(0,1,1,2) | Details |
| 11502731 | Cherstniakova SA, Bi D, Fuller DR, Mojsiak JZ, Collins JM, Cantilena LR: Metabolism of vanoxerine, 1-[2-[bis (4-fluorophenyl) methoxy] ethyl]-4-(3-phenylpropyl) piperazine, by human cytochrome P450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1216-20. |
31(0,1,1,1) | Details |
| 15975043 | Staack RF, Maurer HH: Metabolism of designer drugs of abuse. Curr Drug Metab. 2005 Jun;6(3):259-74. However, in contrast to new medicaments, which are extensively studied in controlled clinical studies concerning metabolism, including cytochrome P450 isoenzyme differentiation, and further pharmacokinetics, designer drugs are consumed without any safety testing. Furthermore, N-benzylpiperazine (BZP), 1-(3, 4-methylenedioxybenzyl) piperazine (MDBP), 1-(3-trifluoromethylphenyl) piperazine (TFMPP), 1-(3-chlorophenyl) piperazine (mCPP) and 1-(4-methoxyphenyl) piperazine (MeOPP) were taken into consideration as derivatives of the class of piperazine-derived designer drugs, as well as alpha-pyr-rolidinopropiophenone (PPP), 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), 3', 4'-methylenedioxy-alpha-pyrrolidino-propiophenone (MDPPP), 4'-methyl-alpha-pyrrolidinopropiophenone (MPPP), and 4'-methyl-alpha-pyrrolidinoexanophenone (MPHP) as derivatives of the class of alpha-pyrrolidinophenone-derived designer drugs. |
2(0,0,0,2) | Details |
| 15640381 | Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J: Cytochrome P450 3A-mediated metabolism of in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7. Epub 2005 Jan 7. mainly underwent N-dealkylation to 1-pyrimidinylpiperazine (1-PP), N-oxidation on the piperazine ring to N-oxide (Bu N-oxide), and hydroxylation to 3'-hydroxybuspirone (3'-OH-Bu), 5-hydroxybuspirone (5-OH-Bu), and 6'-hydroxybuspirone (6'-OH-Bu) in HLMs. |
2(0,0,0,2) | Details |
| 18238859 | Minato K, Suzuki R, Asagarasu A, Matsui T, Sato M: Biotransformation of 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl) piperazin-1-yl] butyl}qui nazolin-4 (3H)-one (TZB-30878), a novel (5-HT) 1A agonist/5-HT3 antagonist, in human hepatic cytochrome P450 enzymes. Drug Metab Dispos. 2008 May;36(5):831-40. Epub 2008 Jan 31. This compound has quinazoline, piperazine, and quinoline rings. |
2(0,0,0,2) | Details |
| 15507542 | Raghavan N, Zhang D, Zhu M, Zeng J, Christopher L: Cyp2D6 catalyzes 5-hydroxylation of 1-(2-pyrimidinyl)-piperazine, an active metabolite of several psychoactive drugs, in human liver microsomes. Drug Metab Dispos. 2005 Feb;33(2):203-8. Epub 2004 Oct 26. In the presence of 1-PP (100 microM) was incubated separately with human cDNA-expressed cytochrome P450 isozymes (including CYP2D6, 3A4, 1A2, 2A6, 2C9, 2C19, 2E1, and 2B6) at 37 degrees C. |
1(0,0,0,1) | Details |
| 19589229 | Antia U, Tingle MD, Russell BR: Metabolic interactions with piperazine-based 'party pill' drugs. J Pharm Pharmacol. 2009 Jul;61(7):877-82. This study aimed to determine whether predictions can be made about global interactions between 'party pills' constituents and other drugs metabolised by the same cytochrome P450 (CYP) isoenzymes. |
1(0,0,0,1) | Details |
| 17220239 | Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, Dilzer S, Lasseter K, Gottesdiener K, Wagner JA, Herman GA: Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C] sitagliptin in humans. Drug Metab Dispos. 2007 Apr;35(4):533-8. Epub 2007 Jan 12. CYP3A4 was the major cytochrome P450 isozyme responsible for the limited oxidative metabolism of sitagliptin, with some minor contribution from CYP2C8. These metabolites were the N- and N-carbamoyl conjugates of parent drug, a mixture of hydroxylated derivatives, an ether of a hydroxylated metabolite, and two metabolites formed by oxidative desaturation of the piperazine ring followed by cyclization. |
1(0,0,0,1) | Details |
| 15019042 | Edlund PO, Baranczewski P: Identification of BVT.2938 metabolites by LC/MS and LC/MS/MS after in vitro incubations with liver microsomes and hepatocytes. J Pharm Biomed Anal. 2004 Mar 10;34(5):1079-90. Liver microsomes were incubated in two different buffer systems with optimum conditions for cytochrome P450 activity or UDP-glucuronosyltransferase activity. The major phase I metabolites of BVT.2938 originated from O-deethylation of the ring, O-dealkylation of the ethylene bridge, pyrazine ring hydroxylation, hydroxylation of ring and piperazine ring N-hydroxylation. |
1(0,0,0,1) | Details |
| 11719709 | Kaneko K, Uchida K, Kobayashi T, Miura K, Tanokura K, Hoshino K, Kato I, Onoue M, Yokokura T: Sex-dependent toxicity of a novel acyl-CoA:cholesterol acyltransferase inhibitor, YIC-C8-434, in relation to sex-specific forms of cytochrome P450 in rats. Toxicol Sci. 2001 Dec;64(2):259-68. |
1(0,0,0,1) | Details |
| 14566442 | Laine K, Ahokoski O, Huupponen R, Hanninen J, Palovaara S, Ruuskanen J, Bjorklund H, Anttila M, Rouru J: Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug Eur J Clin Pharmacol. 2003 Dec;59(10):761-6. Epub 2003 Oct 18. RATIONALE: Preliminary in vitro findings indicated that the novel anxiolytic drug, deramciclane is a substrate for the cytochrome P (450) (CYP) 3A4 isoenzyme. |
1(0,0,0,1) | Details |
| 15228152 | Maurer HH, Kraemer T, Springer D, Staack RF: Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit. 2004 Apr;26(2):127-31. The metabolic pathways, the involvement of cytochrome P450 isoenzymes in the main pathways, and their roles in hepatic clearance are described for designer drugs of different groups. |
1(0,0,0,1) | Details |
| 16912859 | Kim YH, Kang I, Bergeron H, Lau PC, Engesser KH, Kim SJ: Physiological, biochemical, and genetic characterization of an alicyclic amine-degrading Mycobacterium sp. strain THO100 isolated from a morpholine-containing culture of activated sewage sludge. Arch Microbiol. 2006 Nov;186(5):425-34. Epub 2006 Aug 16. This strain was able to utilize pyrrolidine, morpholine, piperidine, piperazine, and 1,2,3,6-tetrahydropyridine as the sole sources of carbon, and energy. The degradation pathway of pyrrolidine as the best substrate for cellular growth was proposed based on the assays of substrate-induced cytochrome P450 and constitutive enzyme activities toward 4-aminobutyric acid (GABA) and succinic semialdehyde (SSA). |
1(0,0,0,1) | Details |
| 11038163 | Jacobsen W, Christians U, Benet LZ: In vitro evaluation of the disposition of A novel protease inhibitor. Drug Metab Dispos. 2000 Nov;28(11):1343-51. K11777 (N-methyl-piperazine--homoPhe-vinylsulfone-phenyl) is a potent, irreversible protease inhibitor. We evaluated the metabolism of K11777 by human liver microsomes, isolated cytochrome P450 (CYP) enzymes, and flavin-containing monooxygenase 3 (FMO3) in vitro. |
1(0,0,0,1) | Details |
| 19904008 | Wojcikowski J, Daniel WA: Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and metabolism--an in vitro study. Pharmacol Rep. 2009 Sep-Oct;61(5):851-8. The aim of the present study was to estimate the inhibitory effect of perazine, a phenothiazine neuroleptic with piperazine structure in a side chain, on human CYP1A2 activity measured as a rate of 3-N- and 1-N-demethylation. |
1(0,0,0,1) | Details |